5Gage BF. Pharmacogeneties - based coumarin therapy. Hematology Am Soc Hematol Educ Program, 2006:467. 被引量:1
6Zhu Y, Shennan M, Reynolds KK, et al . Estimation of warfarin maintenance dose based on VKORC1 ( -1639G > A) and CYP2C9 genotypes. Clin Chem ,2007,53 (7) :1 199. 被引量:1
7Limdi NA, McGwin G, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African - American and European - American patients on warfarin. Clin Pharmacol Ther,2008, 83 (2) :312. 被引量:1
8Scordo MG, Pengo V, Spina E, et al . Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance . Clin Pharmacol Ther , 2002 ,72 (6) :702. 被引量:1
9Rost S, Fregin A, Ivaskevicius V, et al . Mutations in VKORC1 cause warfarin resistance and muhiple coagulation factor deficiency type 2. Nature , 2004, 427 (6 974) :537. 被引量:1
10Rieder MJ, Riener AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005, 352 (22) :2 285. 被引量:1